Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 11, 2015, Pages 15155-15162

  Ming, Jie ^a   Liu, Zeming ^a   Zeng, Wen ^b   Maimaiti, Yusufu ^a   Guo, Yawen ^a   Nie, Xiu ^a   Chen, Chen ^a   Zhao, Xiangwang ^a   Shi, Lan ^a   Liu, Chunping ^a   Huang, Tao ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

BRAF; Papillary thyroid cancer; RAS; RET

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; DNA BINDING PROTEIN; NUCLEAR PROTEIN; RAS PROTEIN; TRIM27 PROTEIN, HUMAN;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; CHINA; DNA MUTATIONAL ANALYSIS; FEMALE; GENE REARRANGEMENT; GENETICS; HUMAN; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; THYROID TUMOR;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; CHINA; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; GENE REARRANGEMENT; HUMANS; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; THYROID NEOPLASMS;

EID: 85013367946     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013; 13: 184-199
2. Liu Z, Li X, Shi L, Maimaiti Y, Chen T, Li Z, Wang S, Xiong Y, Guo H, He W, Liu C, Nie X, Zeng W and Huang T. Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma. Int J Clin Exp Med 2014; 7: 2304-2308
3. Davies L and Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014; 140: 317-322
4. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, Powell CC, van Heerden JA and Goellner JR. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002; 26: 879-885
5. Antonelli A, Fallahi P, Ferrari SM, Mancusi C, Colaci M, Santarpia L and Ferri C. RET TKI: potential role in thyroid cancers. Curr Oncol Rep 2012; 14: 97-104
6. Lee EJ, Song KH, Kim DL, Jang YM, Hwang TS and Kim SK. The BRAF(V600E) mutation is associated with malignant ultrasonographic features in thyroid nodules. Clin Endocrinol (Oxf) 2011; 75: 844-850
7. Howell GM, Carty SE, Armstrong MJ, Lebeau SO, Hodak SP, Coyne C, Stang MT, McCoy KL, Nikiforova MN, Nikiforov YE and Yip L. Both BRAF V600E mutation and older age (>/= 65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol 2011; 18: 3566-3571
8. Jeong SH, Hong HS, Kwak JJ and Lee EH. Analysis of RAS mutation and PAX8/PPAR gamma rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings. J Endocrinol Invest 2015; 38: 849-857
9. Liu D, Liu Z, Condouris S and Xing M. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab 2007; 92: 2264-2271
10. Caronia LM, Phay JE and Shah MH. Role of BRAF in thyroid oncogenesis. Clin Cancer Res 2011; 17: 7511-7517
11. Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC and Cheng JT. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 2005; 63: 461-466
12. Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A and OrloffLA. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg 2013; 139: 1164-1170
13. Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, Al-Nuaim A, Ahmed M, Amin T, Al-Fehaily M, Al-Sanea O, Al-Dayel F, Uddin S and Al-Kuraya KS. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab 2008; 93: 611-618
14. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA and Greco A. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004; 23: 7436-7440
15. Gupta S, Ajise O, Dultz L, Wang B, Nonaka D, Ogilvie J, Heller KS and Patel KN. Follicular variant of papillary thyroid cancer: encapsulated, nonencapsulated, and diffuse: distinct biologic and clinical entities. Arch Otolaryngol Head Neck Surg 2012; 138: 227-233
16. Sapio MR, Guerra A, Marotta V, Campanile E, Formisano R, Deandrea M, Motta M, Limone PP, Fenzi G, Rossi G and Vitale M. High growth rate of benign thyroid nodules bearing RET/PTC rearrangements. J Clin Endocrinol Metab 2011; 96: E916-919
17. Henke LE, Pfeifer JD, Ma C, Perkins SM, DeWees T, El-Mofty S, Moley JF, Nussenbaum B, Haughey BH, Baranski TJ, Schwarz JK and Grigsby PW. BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma. Cancer Med 2015; 4: 791-799
18. Mian C, Pennelli G, Barollo S, Cavedon E, Nacamulli D, Vianello F, Negro I, Pozza G, Boschin IM, Pelizzo MR, Rugge M, Mantero F, Girelli ME and Opocher G. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinol 2011; 164: 971-976
19. Charles RP, Iezza G, Amendola E, Dankort D and McMahon M. Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. Cancer Res 2011; 71: 3863-3871
20. Li C, Lee KC, Schneider EB and Zeiger MA. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab 2012; 97: 4559-4570
21. Fukahori M, Yoshida A, Hayashi H, Yoshihara M, Matsukuma S, Sakuma Y, Koizume S, Okamoto N, Kondo T, Masuda M and Miyagi Y. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort. Thyroid 2012; 22: 683-689
22. Rabes HM, Demidchik EP, Sidorow JD, Lengfelder E, Beimfohr C, Hoelzel D and Klugbauer S. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res 2000; 6: 1093-1103
23. Musholt TJ, Musholt PB, Khaladj N, Schulz D, Scheumann GF and Klempnauer J. Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma. Surgery 2000; 128: 984-993
24. Sugg SL, Zheng L, Rosen IB, Freeman JL, Ezzat S and Asa SL. ret/PTC-1,-2, and-3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential? J Clin Endocrinol Metab 1996; 81: 3360-3365